US 12,285,414 B2
Methods of treating hepatic encephalopathy
William Forbes, Raleigh, NC (US); Kunal Merchant, Durham, NC (US); Enoch Bortey, Chapel Hill, NC (US); and Audrey Shaw, Durham, NC (US)
Assigned to Salix Pharmaceuticals, Inc., Bridgewater, NJ (US)
Filed by Salix Pharmaceuticals, Inc., Bridgewater, NJ (US)
Filed on Feb. 28, 2022, as Appl. No. 17/682,624.
Application 17/682,624 is a continuation of application No. 16/391,438, filed on Apr. 23, 2019, abandoned.
Application 16/391,438 is a continuation of application No. 15/824,209, filed on Nov. 28, 2017, granted, now 10,314,828, issued on Jun. 11, 2019.
Application 15/824,209 is a continuation of application No. 15/212,720, filed on Jul. 18, 2016, granted, now 9,855,254, issued on Jan. 2, 2018.
Application 15/212,720 is a continuation of application No. 13/914,074, filed on Jun. 10, 2013, granted, now 9,421,195, issued on Aug. 23, 2016.
Application 13/914,074 is a continuation of application No. 12/964,847, filed on Dec. 10, 2010, abandoned.
Application 12/964,847 is a continuation of application No. 12/792,658, filed on Jun. 2, 2010, abandoned.
Application 12/792,658 is a continuation in part of application No. 12/572,344, filed on Oct. 2, 2009, abandoned.
Claims priority of provisional application 61/316,796, filed on Mar. 23, 2010.
Claims priority of provisional application 61/307,417, filed on Feb. 23, 2010.
Claims priority of provisional application 61/306,935, filed on Feb. 22, 2010.
Claims priority of provisional application 61/305,854, filed on Feb. 18, 2010.
Claims priority of provisional application 61/262,525, filed on Nov. 18, 2009.
Claims priority of provisional application 61/183,513, filed on Jun. 2, 2009.
Claims priority of provisional application 61/102,349, filed on Oct. 2, 2008.
Prior Publication US 2023/0091701 A1, Mar. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/437 (2006.01); A61K 31/7016 (2006.01); A61K 45/06 (2006.01); G16H 20/10 (2018.01)
CPC A61K 31/437 (2013.01) [A61K 31/7016 (2013.01); A61K 45/06 (2013.01); G16H 20/10 (2018.01); Y02A 90/10 (2018.01)] 10 Claims
 
1. A method of reducing the risk of hospitalization for a subject having hepatic encephalopathy (HE) comprising administering between about 1000 mg to about 1200 mg rifaximin daily to the subject for a period of 12 months or longer, wherein the subject has a Model for End-Stage Liver Disease (MELD) score of between about 1 to 24, thereby reducing the risk of hospitalization.